Results 211 to 220 of about 1,287,454 (361)
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez+17 more
wiley +1 more source
Exploring alternative solvents to n-hexane for green extraction of lipid from camellia oil cakes. [PDF]
Lin Y, Wang Y, Li Y.
europepmc +1 more source
Ubiquitination of transcription factors in cancer: unveiling therapeutic potential
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley +1 more source
SYSTEMS FOR THE SEPARATION OF PHOSPHORIC ESTERS BY SOLVENT DISTRIBUTION
G. W. E. Plaut+2 more
openalex +1 more source
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
Solvent and temperature effects in the photoiniferter RAFT polymerisation of PEG methacrylate.
Chang R, Monnery BD, Zuhorn IS.
europepmc +1 more source
Recent Green and Sustainable Pd-Catalyzed Aminations. [PDF]
Saunders JM+6 more
europepmc +1 more source
Grand challenges in industrial catalysis: let´s put academia and industry on the same page!
Pablo Domínguez de María
doaj +1 more source
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen+12 more
wiley +1 more source
Ultrafast charge transfer dynamics in excited-state donor-acceptor benzylideneaniline. [PDF]
Mitra PK, Verma P, Lakshmanna YA.
europepmc +1 more source